Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics (GRCE)
NASDAQ:GRCE
GRCE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.07 - $4.97
Previous CloseN/A
Volume30.96K
Average Volume (3M)33.07K
Market Cap
$31.28M
Enterprise Value$19.35M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)119.00K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Jun 24, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding13,718,106
10 Day Avg. Volume25,717
30 Day Avg. Volume33,066
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.50Price Target Upside397.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Grace Therapeutics News
PremiumCompany Announcements
Grace Therapeutics Reports Q3 Progress and Financial ResultsPremiumCompany Announcements
Grace Therapeutics Files Form S-3 for Flexible Securities Offering
---
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesGTX-104 showed indications of improved outcomes with more patients having 'good recovery' at Day-90 follow-up on the aSAH modified Rankin scale.
Market PotentialAnalyst believes GTX-104 is a potential new gold-standard for post-surgical aSAH standard of care in the ICU vs. current parenteral nimodipine.
Regulatory ProgressAcasti secured agreement from the FDA on a streamlined approach with an open-label pivotal safety trial.
Bears Say
Safety ConcernsThere were more deaths in the GTX-104 arm compared to the oral nimodipine arm, but no deaths were attributed to nimodipine therapy.
---
Ownership Overview
―
Insiders
1.66% Mutual Funds
9.44% Other Institutional Investors
87.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $2.07 and its highest was $4.96 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $31.28M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Jun 24, 2025 which is in 82 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Feb 13, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of -$0.335 by -$0.025.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Undervalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 13,718,106 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.36 in its last earnings report, missing expectations of -$0.335. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
---
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (397.84% Upside)
$11.50 (397.84% Upside)
Blogger Sentiment
Bullish
GRCE Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.49%
12-Months-Change
Fundamentals
Return on Equity
-22.89%
Trailing 12-Months
Asset Growth
-19.64%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
---
GRCE Stock 12 Month Forecast
Average Price Target
$11.50
▲(397.84% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
SAGE Therapeutics
―
Best Analysts Covering GRCE
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-15.89%
reiterated a buy rating 2 months ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -15.89% per trade.
---